Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1798]
News [2692]
Articles [197]
Editorials [1]
Conferences [135]
elearning [13]
Ipilimumab and BRAF inhibitors for advanced melanoma
Dr Lynn Schuchter - University of Pennsylvania, USA
Ipilimumab and BRAF inhibitors for advanced melanoma ( Dr Lynn Schuchter - University of Pennsylvania, USA )
2 Jun 2013
Ten years of tamoxifen superior to five in reducing breast cancer recurrence...
Dr Richard G. Gray - University of Oxford, UK
Ten years of tamoxifen superior to five in reducing breast cancer recurrence and death ( Dr Richard G. Gray - University of Oxford, UK )
2 Jun 2013
No survival benefit to adding bevacizumab to standard first-line chemoradiation...
Dr Mark R. Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA
No survival benefit to adding bevacizumab to standard first-line chemoradiation for glioblastoma ( Dr Mark R. Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA )
2 Jun 2013
Bevacizumab extends survival for relapsed and advanced cervical cancer
Dr Krishnansu Sujata Tewari - University of California Irvine Medical Center...
Bevacizumab extends survival for relapsed and advanced cervical cancer ( Dr Krishnansu Sujata Tewari - University of California Irvine Medical Center, USA )
2 Jun 2013
Brentuximab vedotin in the frontline setting
Dr Stephen Ansell - Mayo Clinic, Rochester, USA
Brentuximab vedotin in the frontline setting ( Dr Stephen Ansell - Mayo Clinic, Rochester, USA )
2 Jun 2013
Lapatinib in combination with chemotherapy in breast cancer
Dr J. Randolph Hecht - UCLA Medical Center, Santa Monica, USA
Lapatinib in combination with chemotherapy in breast cancer ( Dr J. Randolph Hecht - UCLA Medical Center, Santa Monica, USA )
2 Jun 2013
Cetuximab superior to bevacizumab for advanced colorectal cancer
Dr Volke Heinemann - University of Munich Munich, Germany
Cetuximab superior to bevacizumab for advanced colorectal cancer ( Dr Volke Heinemann - University of Munich Munich, Germany )
1 Jun 2013
Nivolumab produces long-lasting responses in patients with stage IV melanoma
Dr Mario Sznol - Yale Cancer Center, New Haven, USA
Nivolumab produces long-lasting responses in patients with stage IV melanoma ( Dr Mario Sznol - Yale Cancer Center, New Haven, USA )
1 Jun 2013
Maintenance therapy with multi-targeted drug pazopanib delays relapse of...
Dr Andreas du Bois - Kliniken Essen Mitte, Germany
Maintenance therapy with multi-targeted drug pazopanib delays relapse of advanced ovarian cancer ( Dr Andreas du Bois - Kliniken Essen Mitte, Germany )
1 Jun 2013
Adding GM-CSF to ipilimumab improves survival compared to ipilimumab alone
Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA
Adding GM-CSF to ipilimumab improves survival compared to ipilimumab alone ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2013
Treatment of primary central nervous system germinoma with chemotherapy
Dr Jonathan Finlay - Children's Hospital Los Angeles, USA
Treatment of primary central nervous system germinoma with chemotherapy ( Dr Jonathan Finlay - Children's Hospital Los Angeles, USA )
29 May 2013
Biomarker analyses in emerging data from PI3K/AKT/mTOR programme clinical trials
Dr Anna Vivancos - Vall d´Hebron Institute of Oncology, Barcelona, Spain
Biomarker analyses in emerging data from PI3K/AKT/mTOR programme clinical trials ( Dr Anna Vivancos - Vall d´Hebron Institute of Oncology, Barcelona, Spain )
16 May 2013

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation